Repurposing FDA‐Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease

Repurposing FDA‐Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease

Abstract Alzheimer's disease (AD) is one of the most common neurodegenerative causes of dementia, the pathology of which is still not much clear. It′s challenging to discover the disease modifying agents for the prevention and treatment of AD over the years. Emerging evidence has been accumulat...

Full description

Bibliographic Details
Main Authors: Dr. Chenshu Xu, Haoman Zou, Xi Yu, Yazhou Xie, Jiaxin Cai, Qi Shang, Na Ouyang, Dr. Yinan Wang, Dr. Pan Xu, Dr. Zhendan He, Dr. Haiqiang Wu
Format: Article
Language:English
Published: Wiley-VCH 2021-09-01
Series:ChemistryOpen
Subjects:
Alzheimer's disease
glutaminyl cyclase
FDA-approved compounds
oxidative stress
screening and repurposing
Online Access:https://doi.org/10.1002/open.202000235

Internet

https://doi.org/10.1002/open.202000235

Similar Items